Maternal Serum Adropin in Placenta Accreta Spectrum

Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07421180

Acronym

Adropin

Enrollment

Registered

2026-02-19

Start date

2024-05-15

Completion date

2025-04-01

Last updated

2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta Spectrum, Placenta Previa

Keywords

Placenta accreta spectrum, Placenta previa, Adropin, Endothelial dysfunction, Biomarker

Brief summary

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion. Methods: This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Pregnant women aged 18-45 years in the reproductive period * Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS

Exclusion criteria

* Uterine anomalies, * Chronic systemic diseases, * Multiple pregnancies, * Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.

Design outcomes

Primary

Measure	Time frame	Description
Blood serum Adropin levels	From 15.04.2024 to 01.04.2025	The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.

Countries

Turkey (Türkiye)

Outcome results